Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The D3 dopamine receptor: From structural interactions to function
Chiara Fiorentini, Paola Savoia, Federica Bono, et al.
European Neuropsychopharmacology (2014) Vol. 25, Iss. 9, pp. 1462-1469
Closed Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis
Thomas M. Keck, William S. John, Paul W. Czoty, et al.
Journal of Medicinal Chemistry (2015) Vol. 58, Iss. 14, pp. 5361-5380
Open Access | Times Cited: 96
Loss and remodeling of striatal dendritic spines in Parkinson’s disease: from homeostasis to maladaptive plasticity?
Rosa M. Villalba, Yoland Smith
Journal of Neural Transmission (2017) Vol. 125, Iss. 3, pp. 431-447
Open Access | Times Cited: 80
Elevated Dopamine D2/3 Receptor Availability in Obese Individuals: A PET Imaging Study with [11C](+)PHNO
Edward Gaiser, Jean‐Dominique Gallezot, Patrick D. Worhunsky, et al.
Neuropsychopharmacology (2016) Vol. 41, Iss. 13, pp. 3042-3050
Open Access | Times Cited: 54
Targeting the dopamine D3 receptor: an overview of drug design strategies
Antoni Cortés, Estefanía Moreno, Mar Rodríguez-Ruiz, et al.
Expert Opinion on Drug Discovery (2016) Vol. 11, Iss. 7, pp. 641-664
Closed Access | Times Cited: 51
Dopamine D3 Receptor Heteromerization: Implications for Neuroplasticity and Neuroprotection
Federica Bono, Veronica Mutti, Chiara Fiorentini, et al.
Biomolecules (2020) Vol. 10, Iss. 7, pp. 1016-1016
Open Access | Times Cited: 39
Potential for targeting dopamine/DARPP-32 signaling in neuropsychiatric and neurodegenerative disorders
Akinori Nishi, Takahide Shuto
Expert Opinion on Therapeutic Targets (2017) Vol. 21, Iss. 3, pp. 259-272
Closed Access | Times Cited: 40
The Dopamine Receptor D3 Regulates Lipopolysaccharide-Induced Depressive-Like Behavior in Mice
Jing Wang, Yuwei Jia, Guodong Li, et al.
The International Journal of Neuropsychopharmacology (2018) Vol. 21, Iss. 5, pp. 448-460
Open Access | Times Cited: 39
Functional Characterization of a Novel Series of Biased Signaling Dopamine D3 Receptor Agonists
Wei Xu, Xiaozhao Wang, Aaron M. Tocker, et al.
ACS Chemical Neuroscience (2016) Vol. 8, Iss. 3, pp. 486-500
Open Access | Times Cited: 37
Role of Dopamine D2/D3 Receptors in Development, Plasticity, and Neuroprotection in Human iPSC-Derived Midbrain Dopaminergic Neurons
Federica Bono, Paola Savoia, Adele Guglielmi, et al.
Molecular Neurobiology (2017) Vol. 55, Iss. 2, pp. 1054-1067
Open Access | Times Cited: 34
Nicotine prevents alpha-synuclein accumulation in mouse and human iPSC-derived dopaminergic neurons through activation of the dopamine D3- acetylcholine nicotinic receptor heteromer
Federica Bono, Veronica Mutti, Paola Savoia, et al.
Neurobiology of Disease (2019) Vol. 129, pp. 1-12
Closed Access | Times Cited: 33
5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction
Silvia Fanni, Simona Scheggi, Francesca Rossi, et al.
Neurobiology of Disease (2018) Vol. 121, pp. 120-130
Closed Access | Times Cited: 32
Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson’s Disease
Fabio Del Bello, Mario Giannella, Gianfabio Giorgioni, et al.
Biomolecules (2019) Vol. 9, Iss. 4, pp. 142-142
Open Access | Times Cited: 29
Heteromerization of dopaminergic receptors in the brain: Pharmacological implications
Desye Misganaw
Pharmacological Research (2021) Vol. 170, pp. 105600-105600
Closed Access | Times Cited: 21
Pregnenolone for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease
Sara Corsi, Simona Scheggi, Alessandra Pardu, et al.
Experimental Neurology (2023) Vol. 363, pp. 114370-114370
Open Access | Times Cited: 8
Brain connectivity changes to fast versus slow dopamine increases
Peter Manza, Dardo Tomasi, Leah Vines, et al.
Neuropsychopharmacology (2024) Vol. 49, Iss. 6, pp. 924-932
Open Access | Times Cited: 2
Review on allosteric modulators of dopamine receptors so far
Fentaw Girmaw
Health Science Reports (2024) Vol. 7, Iss. 3
Open Access | Times Cited: 2
Adolescent Intermittent Ethanol Increases the Sensitivity to the Reinforcing Properties of Ethanol and the Expression of Select Cholinergic and Dopaminergic Genes within the Posterior Ventral Tegmental Area
Sheketha R. Hauser, Christopher P. Knight, William A. Truitt, et al.
Alcoholism Clinical and Experimental Research (2019) Vol. 43, Iss. 9, pp. 1937-1948
Open Access | Times Cited: 22
Pharmacology profile of F17464, a dopamine D3 receptor preferential antagonist
Cristina Cosi, Jean‐Claude Martel, Agnès L. Auclair, et al.
European Journal of Pharmacology (2020) Vol. 890, pp. 173635-173635
Closed Access | Times Cited: 20
Impaired dopamine D3 and nicotinic acetylcholine receptor membrane localization in iPSCs-derived dopaminergic neurons from two Parkinson’s disease patients carrying the LRRK2 G2019S mutation
Federica Bono, Veronica Mutti, Paola Devoto, et al.
Neurobiology of Aging (2020) Vol. 99, pp. 65-78
Closed Access | Times Cited: 20
Dopamine receptors: homomeric and heteromeric complexes in l-DOPA-induced dyskinesia
Óscar Solís, Rosario Moratalla
Journal of Neural Transmission (2018) Vol. 125, Iss. 8, pp. 1187-1194
Closed Access | Times Cited: 20
Expression of dopamine D2 and D3 receptors in the human retina revealed by positron emission tomography and targeted mass spectrometry
Fernando Caravaggio, Enzo Scifo, Etienne Sibille, et al.
Experimental Eye Research (2018) Vol. 175, pp. 32-41
Open Access | Times Cited: 19
Dopamine β hydroxylase as a potential drug target to combat hypertension
Sanjay Kumar Dey, Manisha Saini, Pankaj Prabhakar, et al.
Expert Opinion on Investigational Drugs (2020) Vol. 29, Iss. 9, pp. 1043-1057
Closed Access | Times Cited: 17
Structural Plasticity of Dopaminergic Neurons Requires the Activation of the D3R-nAChR Heteromer and the PI3K-ERK1/2/Akt-Induced Expression of c-Fos and p70S6K Signaling Pathway
Veronica Mutti, Federica Bono, Zaira Tomasoni, et al.
Molecular Neurobiology (2022) Vol. 59, Iss. 4, pp. 2129-2149
Open Access | Times Cited: 10
The novel hybrid agonist HyNDA-1 targets the D3R-nAChR heteromeric complex in dopaminergic neurons
Carlo Matera, Federica Bono, Silvia Pelucchi, et al.
Biochemical Pharmacology (2019) Vol. 163, pp. 154-168
Open Access | Times Cited: 16
Acute administration of a dopamine D2/D3 receptor agonist alters behavioral and neural parameters in adult zebrafish
Débora Dreher Nabinger, Stefani Altenhofen, Alexis Buatois, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2023) Vol. 125, pp. 110753-110753
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top